Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Agios Pharmaceuticals, Inc.
13G/A
AGIO · 00847X104
|
0% |
6/13/2025
Event 6/1/2025
|
|||
| BB Biotech AG | 0% | ||||
| Biotech Target N.V. | 0% | ||||
|
Macrogenics Inc
13G/A
MGNX · 556099109
|
0% |
6/13/2025
Event 6/1/2025
|
|||
| BB Biotech AG | 0% | ||||
| Biotech Target N.V. | 0% | ||||
|
Black Diamond Therapeutics, Inc.
13G/A
BDTX · 09203E105
|
4.8% |
3/21/2025
Event 3/19/2025
|
|||
| BB Biotech AG | 4.8% | ||||
| Biotech Growth N.V. | 4.8% | ||||
|
Esperion Therapeutics, Inc.
13G/A
ESPR · 29664W105
|
4.9% |
3/10/2025
Event 3/4/2025
|
|||
| BB Biotech AG | 4.9% | ||||
| Biotech Target N.V. | 4.9% | ||||
|
Sage Therapeutics, Inc.
13G/A
SAGE · 78667J108
|
1.9% |
1/17/2025
Event 1/13/2025
|
|||
| BB Biotech AG | 1.9% | ||||
| Biotech Target N.V. | 1.9% | ||||